Buy Biocon, target price Rs 351: Axis Securities

Axis Securities recommends a Buy call on Biocon, setting a target price of Rs 351, indicating a potential 10% upside. The recommendation is based on the increasing market share of biosimilars and a robust pipeline, including gLiraglutide and upcoming biosimilars like Stellara and YESFILI. For the quarter ended December 31, 2024, Biocon reported a consolidated total income of Rs 3856.